| ¿µ¹® | outer ear, external ear | ÇÑ±Û | ¹Ù±ù±Í, ¿ÜÀÌ |
|---|---|---|---|
| ¼³¸í | ±Í´Â ¹Ù±ùÀÇ ¹Ù±ù±Í, ±×¸®°í À½À» Àü´ÞÇÏ´Â °¡¿îµ¥±Í ±×¸®°í Àü´ÞµÈ¾îÁø ¼Ò¸®¸¦ ½Å°æÀÌ ¾Ë¾ÆµéÀ» ¼ö ÀÖµµ·Ï ¹Ù²ãÁÖ´Â ±â´ÉÀ» °¡Áø ¼Ó±Í, ÀÌ 3°¡Áö·Î ±¸ºÐµÈ´Ù. ¹Ù±ù±Í´Â ±×³É ¹Û¿¡¼ º¸ÀÌ´Â ºÎºÐÀ̸ç, ¿ÜÀÌ´Â ¹Ù±ù 2/3´Â ¿¬°ñ·Î ±¸¼ºµÇ¾î ÀÖ°í ¾ÈÂÊ 1/3Àº »À·Î ±¸¼ºµÇ¾î ÀÖ´Ù. |
||
| FDP(s) | 1) Fibrinolytic split Products(= FSP) 2) Fibrinogen Degradation Products |
|---|---|
| FSP | familial spastic paraplegia; fibrin split products; fibrinogen split products; fine suspended partic... |
| AAN | AIDS-associated nephropathy; alpha-amino nitrogen; American Academy of Neurology; American Academy o... |
| AD | accident dispensary; acetate dialysis; active disease; acute dermatomyositis; addict, addiction; ade... |
| anal | analgesia, analgesic; analysis, analytic |
| AN | Analgesic nephropathy |
|---|---|
| AGE | Advanced Glycation End Products |
| AGE | Advanced Glycosylated End-products |
| CPMP | Committee for Proprietary Medicinal Products |
| DPC | Diagnostic Products Corporation |
| adjuvant analgesic | <pharmacology> A drug that is not a primary analgesic but that research has shown to have independent or additive analgesic properties. (16 Dec 1997) |
|---|---|
| analgesic | An agent that alleviates pain without causing loss of consciousness. (18 Nov 1997) |
| analgesic cuirass | An analgesic or hypalgesic zone in the proximal thoracic region, found in tabetic neurosyphilis. Synonym: analgesic cuirass, Hitzig's girdle. (05 Mar 2000) |
| analgesic nephritis | Chronic interstitial nephritis with renal papillary necrosis, occurring in patients with a long history of excessive consumption of analgesics, especially those containing phenacetin. Synonym: analgesic nephropathy. (05 Mar 2000) |
| analgesic nephropathy | <nephrology, pathology> A form of kidney damage which can occur from the overexposure to certain analgesics (for example acetaminophen, salicylates and non-steroidal anti-inflammatory agents). In most cases analgesic use is excessive in dosing or chronicity of use. Complications include acute renal failure. See: interstitial nephritis. Origin: Gr. Pathos = disease (27 Sep 1997) |
| narcotic analgesic agent | <pharmacology> Medications that relieve pain but have addictive potential if used regularly. Examples include: meperidine, morphine, propoxyphene, codeine, hydrocodone, oxycodone, hydromorphone, nalbuphine, butorphanol and heroin. (27 Sep 1997) |
| biological products | Complex pharmaceutical substances, preparations, or agents of organic origin, usually obtained by biological methods or assay, that depend for their action on the processes affecting immunity. They are used especially in diagnosis and treatment of disease (as vaccines or pollen extracts). Biological products are differentiated from biological factors in that the latter are compounds with biological or physiological activity made by living organisms. (12 Dec 1998) |
| blood products | Biopharmaceutical products purified from human blood, such as the blood clotting factor VIII used to treat haemophiliacs. (Recombinant factor VIII is also on the market.) The term also refers to biopharmaceuticals that act on blood or the cells that make blood. These products are often produced by the cells themselves, but in such tiny amounts that extracting them from blood is impractical, and so they are genetically engineered. (14 Nov 1997) |
| gene products, env | Retroviral proteins, often glycosylated, coded by the envelope (env) gene. They are usually synthesised as protein precursors (polyproteins) and later cleaved into the final products by a viral protease. (12 Dec 1998) |
| gene products, gag | Proteins coded by the retroviral gag gene. The products are usually synthesised as protein precursors or polyproteins, which are then cleaved by viral proteases to yield the final products. Many of the final products are associated with the nucleoprotein core of the virion. Gag is short for group-specific antigen. (12 Dec 1998) |
| gene products, nef | Products of the HIV nef gene (formerly 3'-orf gene). The products trans-suppress viral replication and function as negative regulators of transcription. Nef stands for negative factor. (12 Dec 1998) |
| gene products, pol | Retroviral proteins coded by the pol gene. Often synthesised as a gag-pol fusion protein (fusion proteins, gag-pol) and later cleaved into final products that include reverse transcriptase, endonuclease/integrase, and viral protease. Pol is short for polymerase, the enzyme class of reverse transcriptase. (12 Dec 1998) |
| gene products, rev | Trans-acting nuclear proteins whose functional expression are required for HIV viral replication. Specifically, the rev gene products are required for processing and translation of the HIV gag and env mRNAs, and thus rev regulates the expression of the viral structural proteins. Rev can also regulate viral regulatory proteins. A cis-acting antirepression sequence (car) in env, also known as the rev-responsive element (rre), is responsive to the rev gene product. Rev is short for regulator of virion. (12 Dec 1998) |
| gene products, rex | Post-transcriptional regulatory proteins required for the accumulation of mRNAs that encode the gag and env gene products in HTLV-I and HTLV-II. The rex (regulator x; x is undefined) products act by binding to elements in the ltr. (12 Dec 1998) |
| gene products, tat | Trans-acting transcription factors. Nuclear proteins whose expression is required for HIV viral replication. The tat protein stimulates HIV-ltr-driven RNA synthesis for both viral regulatory and viral structural proteins. Tat stands for trans-activation of transcription. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|